Matica Bio and VaxDome Partner to Develop Antigen-Agnostic Antiviral-Vaccine Hybrids with Influenza as One of the Disease Models
COLLEGE STATION, Texas, July 6, 2026 /PRNewswire/ -- Matica Biotechnology, Inc. ("Matica Bio"), a viral vector contract development and manufacturing organization (CDMO), is partnering with Texas-based biotech VaxDome Inc. to bring its novel antigen-agnostic antiviral-vaccine hybrid...
COLLEGE STATION, Texas, July 6, 2026 /PRNewswire/ -- Matica Biotechnology, Inc. ("Matica Bio"), a viral vector contract development and manufacturing organization (CDMO), is partnering with Texas-based biotech VaxDome Inc. to bring its novel antigen-agnostic antiviral-vaccine hybrid...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.